FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

AICAR

Acadesine / AICA Ribonucleotide / ZMP

Longevity & Anti-Aging

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.

작용 메커니즘

AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 150-500mg daily via subcutaneous injection. Animal studies used 500mg/kg. Often cycled 4-8 weeks. Sometimes combined with GW501516 in research settings.

연구 노트

Clinical Research Status

AICAR underwent Phase III clinical trials for reduction of ischemic injury during coronary artery bypass graft surgery, though it ultimately did not receive FDA approval for this indication. Research interest shifted dramatically after 2008 Salk Institute studies demonstrated that AICAR administration alone could improve running endurance in sedentary mice by 44%. It remains an investigational compound with no approved medical indications, though academic research into AMPK activation continues across metabolic disease, cancer, and aging fields.

Key Published Findings

The landmark Narkar et al. (2008) paper in Cell demonstrated that AICAR treatment for 4 weeks reprogrammed muscle metabolism toward oxidative fiber types and enhanced running endurance without exercise training. AMPK activation by AICAR increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through PGC-1alpha signaling pathways. In cardiac ischemia studies, AICAR reduced post-surgical complications including atrial fibrillation and the need for inotropic support.

Safety Profile

Clinical trial data from cardiac surgery studies showed AICAR to be relatively well-tolerated at therapeutic doses, with hypoglycemia and lactic acidosis being the primary dose-limiting concerns. Renal toxicity has been observed at higher doses due to uric acid accumulation from purine metabolism. Long-term safety data in healthy populations is essentially nonexistent, as most human data comes from short-term perioperative use in cardiac patients.

Comparison to Related Compounds

Unlike GW501516 (Cardarine), which activates PPAR-delta downstream of AMPK, AICAR directly activates AMPK itself, affecting a broader range of metabolic pathways including autophagy and mTOR suppression. SLU-PP-332 represents a newer generation of exercise mimetics targeting estrogen-related receptors rather than AMPK. Metformin also activates AMPK but through indirect mitochondrial complex I inhibition rather than direct allosteric activation, resulting in a different pharmacological profile.

Community Observations

Users report enhanced endurance and fat oxidation, though the effects are considered modest compared to expectations set by animal studies. The high cost per effective dose and requirement for injection limit its practical use in performance enhancement contexts. Some users combine AICAR with GW501516 based on the original Salk Institute research showing synergistic effects, though this combination carries compounded safety unknowns.

반감기

~2-3 hours

재조성

Bacteriostatic water (BAC) or sterile saline

보관

건조한 상태

Refrigerate 2-8C up to 12 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

AcadesineAICA RibonucleotideZMP

자주 묻는 질문

AICAR란 무엇인가요?

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.

AICAR는 어떻게 작용하나요?

AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.

AICAR의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

AICAR의 반감기는 얼마인가요?

~2-3 hours

AICAR의 다른 이름은 무엇인가요?

Acadesine, AICA Ribonucleotide, ZMP

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기